title: Prevalence of antibodies against measles, mumps, and rubella before and after vaccination of school-age children with three different triple combined viral vaccines, Rio Grande do Sul, Brazil, 1996.
abstract: OBJECTIVE
  We evaluated the seroprevalence for measles, mumps, and rubella in school-age children (6-12 years old) before and after the administration of three triple combined viral vaccines.
  
  
  METHODS
  In two municipal schools of Rio Grande do Sul, Brazil, 692 blood samples were collected before vaccination and 636 samples 21 to 30 days after vaccination during 1996. IgG antibody seropositivity was investigated by enzyme-linked immunosorbent assay (measles and mumps with Enzygnost [Behring, Marburg, Germany]; rubella with Rubenostika [Organon Teknica, Boxtel, the Netherlands]). The vaccines compared were: A: E-Zagreb, L-Zagreb, and Wistar RA 27/3 (Tresivac); B: Moraten, J-Lynn, and Wistar RA 27/3 (M-M-R II); and C: Schwarz, Urabe AM-9, and Wistar RA 27/3 (Trimovax).
  
  
  RESULTS
  Before vaccination, 79.2% [95% confidence interval (CI)=76.0%-82.2%] of the samples were positive for measles, 69.4% (95% CI=65.8%-72.8%) for mumps, and 55.4% (95% CI=51.6%-59.2%) for rubella. After vaccination with the A, B, and C vaccines, seropositivity was 100.0%, 99.5%, and 100.0%, respectively for measles; 99.5%, 94.5%, and 92.0% for mumps; and 92.6%, 91.3%, and 88.6% for rubella.
  
  
  CONCLUSIONS
  About one-fifth (20.8%) of the schoolchildren who could have been vaccinated against measles at age 9 months had levels of antibodies insufficient for protection. In the sample of schoolchildren without previous vaccination against mumps and rubella, high proportions of susceptible levels were found. All vaccines were immunogenic, but vaccine A yielded a seroconversion rate of 99.5% for the mumps component, which was significantly higher than the other two vaccines (P<0.01).
authors.affiliation: Faculdade de Medicina da Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil. nuclivac@hcpa.ufrgs.br
authors.forename: Boaventura Antônio
authors.initials: BA
authors.lastname: dos Santos
authors.forename: Selir M
authors.initials: SM
authors.lastname: Stralioto
authors.forename: Marilda M
authors.initials: MM
authors.lastname: Siqueira
authors.forename: Tani S
authors.initials: TS
authors.lastname: Ranieri
authors.forename: Marilina
authors.initials: M
authors.lastname: Bercini
authors.forename: Maria Tereza
authors.initials: MT
authors.lastname: Schermann
authors.forename: Mário Bernardes
authors.initials: MB
authors.lastname: Wagner
authors.forename: Themis R
authors.initials: TR
authors.lastname: Silveira
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D001938:Brazil; D002648:Child; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008457:Measles / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D022542:Measles-Mumps-Rubella Vaccine / Q000276:immunology*; D009107:Mumps / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D012409:Rubella / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D016036:Seroepidemiologic Studies; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D022542:Measles-Mumps-Rubella Vaccine